HOME >> MEDICINE >> NEWS
Statins underprescribed to patients at higher risk of heart disease, Stanford study says

STANFORD, Calif. - The use of cholesterol-lowering drugs known as statins to reduce the risk of heart disease has exploded in recent years, but a new Stanford University School of Medicine study shows that doctors are prescribing them in only half of their visits with patients who would benefit most from them.

Based on the findings, the researchers say physicians should be more aggressive in investigating statin therapy for patients with a high or moderate risk of heart disease, and that patients should ask to have their cholesterol levels checked regularly.

The findings, published in the May 31 issue of the Public Library of Science-Medicine, come at a time when many Americans are still reeling from recent reports that some prescription drugs, including the painkiller Vioxx and postmenopausal hormone therapy, were overprescribed to patients who had little to gain from them.

"You have to look at drug therapy on a case-by-case basis. We have many situations where drugs are misused or overused," said lead author Jun Ma, MD, PhD, research associate at the Stanford Prevention Research Center. "In this particular case, although we did observe some inappropriate use of statins in low-risk patients, the predominant problem appears to be underuse in higher risk patients."

Since their introduction 17 years ago, statins have become the most prescribed class of drugs in the United States, with more than 126 million prescriptions filled in 2004. Statins reduce the level of cholesterol produced by the liver while boosting the liver's ability to remove LDL cholesterol, the so-called "bad" cholesterol, from the blood. High LDL cholesterol levels increase the risk for heart disease. Each year, more than half a million people die from heart disease, making it the No. 1 killer among both men and women.

Randall Stafford, MD, PhD, associate professor of medicine at the Stanford Prevention Research Center and senior author of the st
'"/>

Contact: Susan Ipaktchian
susani@stanford.edu
650-725-5375
Stanford University Medical Center
30-May-2005


Page: 1 2 3

Related medicine news :

1. Statins linked to lower risk of infection
2. Statins protect smokers from lung damage
3. Statins reduce risk of stroke in heart patients
4. Statins prove life-saving in patients with acute coronary syndromes
5. Statins may improve circulation in the retina
6. Statins, beta-blockers lessen heart attack risk, says Stanford-Kaiser study
7. Statins have neutral effect on risk of cancer
8. Statins may simulate stem cells for heart repair
9. Statins reduce the risk of stroke and death after carotid artery surgery
10. Statins use associated with lower risk of fractures
11. Statins protect from death from pneumonia

Post Your Comments:
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Cached News: